3-Methylmethcathinone

Last updated

3-Methylmethcathinone
3-methylmethcathinone.svg
Clinical data
Other names3-MMC; Metaphedrone; 3-Methyl-N-methylcathinone; 3,N-Dimethylcathinone; 3,N-Dimethyl-β-ketoamphetamine; 3,α,N-Trimethyl-β-ketophenethylamine
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Bioavailability Oral: 5–9% [2]
Protein binding Low [2]
Elimination half-life 50 min (in pigs) [2]
Identifiers
  • 2-(Methylamino)-1-(3-methylphenyl)propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard 100.259.777 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C11H15NO
Molar mass 177.247 g·mol−1
3D model (JSmol)
Melting point 193.2 °C (379.8 °F) ± 0.2°C (hydrochloride salt)
Boiling point 280.5 °C (536.9 °F) ± 23.0°C at 760 mm Hg
Solubility in water Sparingly soluble in PBS; slightly soluble in ethanol, dimethyl sulfoxide, and dimethyl formamide. [3]  mg/mL (20 °C)
  • CC1=CC=CC(C(C(C)NC)=O)=C1
  • InChI=1S/C11H15NO/c1-8-5-4-6-10(7-8)11(13)9(2)12-3/h4-7,9,12H,1-3H3
  • Key:QDNXSIYWHYGMCD-UHFFFAOYSA-N

3-Methylmethcathinone (3-MMC), also known as metaphedrone, [4] is a designer drug from the substituted cathinone family. 3-MMC is a monoamine transporter substrate (a substance acted upon by monoamine transporters) that potently releases and inhibits the reuptake of dopamine and norepinephrine, as well as displaying moderate serotonin releasing activity. [5] Unlike some synthetic cathinones, 3-MMC has been evaluated in at least one large mammal study. [2]

Contents

3-Methylmethcathinone is a structural isomer of mephedrone (4-methylmethcathinone), and as such is illegal via blanket bans in many countries that have banned mephedrone. However, 3-MMC has still appeared on the recreational drug market as an alternative to mephedrone, and was first identified being sold in Sweden in 2012. [6]

History

3-MMC was first encountered in Sweden in 2012, [7] it was created as a designer drug following the control in many countries of the related compound mephedrone. It was sold as a research chemical, usually in powdered form. There is no known or reported medical use of 3-MMC, it is primarily used recreationally.

Chemistry

Structure

3-Methylmethcathinone's IUPAC name is 2-(methylamino)-1-(3-methylphenyl)propan-1-one). It is one of many synthetic cathinones, designer drugs related to amphetamines. It is a structural isomer of mephedrone, and controlled as such. It can also be seen as the β-keto analog of 3-methylmethamphetamine

3-MMC contains a chiral center at the C-2 carbon. Therefore two enantiomers exist, the R and S enantiomer. It is assumed that the S form is more potent due to its similarity to cathinone, but further research is needed to confirm this. [8]

Synthesis

There are several ways to synthesize 3-MMC. One route adapted from Power et al [9] is to add ethylmagnesium bromide to 3-methylbenzaldehyde (I) to form the product 1-(3-methylphenyl)-1-propanol (II). This product is then oxidized by pyridinium chlorochromate (PCC) on silica gel to the ketone (III) and brominated with hydrobromic acid to yield the bromoketone (IV). This bromoketone is reacted with ethanolic methylamine to produce the 3-MMC free base (V), which can be converted to the hydrochloride salt (VI) by addition of ethereal hydrogen chloride (VI). [9]

One possible synthesis, starting from 3-methylbenzaldehyde 3mmc synthesis.svg
One possible synthesis, starting from 3-methylbenzaldehyde

Pharmacology

3-MMC potently inhibits the reuptake of monoamines in the human norepinephrine (NET) and dopamine (DAT) transporters. It also acts as a triple releasing agent of dopamine, serotonin, and norepinephrine, similar to many other cathinones. As a releasing agent, it is more selective for dopamine and especially norepinephrine, suggesting that it has stronger amphetamine-like stimulant properties compared to mephedrone or MDMA. [5]

TransporterEC50 [nM] [10] IC50 [nM]
SERT Tooltip Serotonin transporter2924500
NET Tooltip Norepinephrine transporter2780
DAT Tooltip Dopamine transporter70270

Non-human studies

The oral bioavailability of 3-methylmethcathinone was determined at 7% [2] in one pig study, with peak blood concentrations (Tmax) attained within 5 to 10 minutes, and a relatively short half-life of 50 minutes. Concentration in blood plasma dropped below detectability 24 hours after oral ingestion. Decreased feeding behavior resulted in weight loss for some.

Metabolism

The metabolic pathway of 3-MMC is not well described. Known metabolites include 3-methylephedrine and 3-methylnorephedrine. A possible metabolic pathway is β-keto-reduction followed by N-demethylation. [11]

3-MMC also binds to serotonin 5-HT1A, 5-HT2A, 5-HT2C receptors and adrenergic α1A and α2A receptors. [12]

Toxicity

A total of 27 fatalities with at least some exposure to 3-MMC have been confirmed as of March 2022. 18 of the 27 reported fatalities involved multiple drugs of abuse, usually opioids and uppers ("speedballs"). [13] Of the 13 cases that specified gender, 12 deaths were male and 1 death was female. Of the 7 males whose age was reported, the median age was 27. The fatalities see a wide range of blood concentrations, from 249 to 1600 ng/mL. [14] The route of administration in any of these fatalities is not clear.

Of the presumably nine monointoxication deaths involving only 3-MMC that have occurred, two monointoxication cases were reported in the Netherlands and one was reported in France. The death in France was determined to be an accidental overdose.

In addition, there has been 291 reported cases of non-fatal 3-MMC intoxications. 213 of these cases (75%) were reported in Poland alone, and 50 cases (17%) were reported in Sweden.

The toxicokinetics of 3-MMC are thought to be similar to those for mephedrone. The dose-response curve of 3-MMC in humans is not well described in the literature, likely due to limited academic interest to date.

Recreational use

Effects

3-MMC as prepared for recreational use. 3-MMC.jpg
3-MMC as prepared for recreational use.

As with mephedrone, users of 3-MMC typically report effects such as an elevated mood, pleasant body sensations, feelings of love and empathy, euphoria, greater appreciation of music, heightened libido, and increased confidence and sociability. [15]

Adverse effects range from aggression, dry mouth, and jaw clenching, to more serious effects such as hyponatremia, seizures, hyperthermia and rhabdomyolysis. [15] [7]

Abuse

Due to its short duration and dopaminergic effects, 3-MMC is addictive and commonly abused. Repeated dosing within a sitting is typical, sometimes using different routes. Common self-reported doses range from 50 to 150 mg, up to single 500 mg doses. Intranasal administration, or snorting, is the most common route of administration, followed by oral administration. It can also be administered rectally and injected.

Users may dose repeatedly in order to extend the drugs duration, leading to 0.5—2 gram "sessions" that can span an evening. Single-dose effects last from 30 to 60 minutes, typically peaking around 10-minutes post-dose. In a questionnaire-based study of self-reported 3-MMC users in Slovenia, it was found that 88% of users insufflated the drug while 42% took it orally. The study did not find any instances of users injecting 3-MMC. Moreover, 26% of the users reported taking more than 1.5 grams of 3-MMC in a single sitting and over 50% reported having consumed more than 0.5 grams in a single sitting. [16]

Available forms

3-Methylmethcathinone is commonly encountered as a white/off-white crystalline or pasty solid. It can be found sold in capsules. It is assumed to be a racemic mixture like mephedrone.

In the United States, 3-MMC is illegal as a positional isomer of the controlled substance mephedrone [17] It was explicitly designated as a controlled substance on 13 December 2023. [18]

Since October 2015, 3-MMC is a controlled substance in China. [19]

3-MMC is banned in the Czech Republic. [20]

3-MMC was not banned in 2016 by the United Nations Office on Drugs and Crime (UNODC) after a critical review. [21] However, following its subsequent abuse beginning in 2019, this decision was overturned and it was placed into schedule II of the 1971 convention in March 2023. [1]

Effective 28 October 2021, 3-MMC has been scheduled under the Dutch Opium Law and is therefore illegal in the Netherlands. [22]

3-MMC was given narcotic status in India on 8 February 2024.

Research

3-MMC is under development for use as a pharmaceutical drug in the potential treatment of dyskinesias. [23] As of August 2023, it is in preclinical research for this indication. [23] The drug is being developed by Clearmind Medicine. [23]

3-MMC is currently being developed as a medicine by the American biotech company MindMed. They have filed for a patent to use 3-MMC for problems such as social anxiety disorder, post-traumatic stress disorder (PTSD), and as an adjunct in couples therapy. [24]

3-MMC is also undergoing clinical trials for its use in treating menstrual symptoms. [25] A successful trial has been completed in the University of Maastricht. These efforts are led by the small Dutch company Period Pill. [26] The company has filed for patent coverage in Canada, Mexico, Croatia, the United States, Morocco, Japan, Brazil, Poland, Hungary, and Korea.

See also

Related Research Articles

<span class="mw-page-title-main">Psychopharmacology</span> Study of the effects of psychoactive drugs

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.

A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron. This results in increased extracellular concentrations of dopamine and increase in dopaminergic neurotransmission.

α-Ethyltryptamine Chemical compound

α-Ethyltryptamine, also known as etryptamine, is an entactogen and stimulant drug of the tryptamine family. It was originally developed and marketed as an antidepressant under the brand name Monase by Upjohn in the 1960s before being withdrawn due to toxicity.

<span class="mw-page-title-main">Butylone</span> Entactogen, psychedelic, and stimulant drug of the phenethylamine class

Butylone, also known as β-keto-N-methylbenzodioxolylbutanamine (βk-MBDB), is an entactogen, psychedelic, and stimulant psychoactive drug of the phenethylamine, amphetamine, phenylisobutylamine, and cathinone families. It is the β-keto analogue of MBDB and the substituted methylenedioxyphenethylamine analogue of buphedrone.

<span class="mw-page-title-main">Methedrone</span> Chemical compound of the cathinone class

Methedrone is a recreational drug of the cathinone chemical class. Chemically, methedrone is closely related to para-methoxymethamphetamine (PMMA), methylone and mephedrone. Methedrone received media attention in 2009 after the death of two young Swedish men. In both cases toxicology analysis showed methedrone was the only drug present in both men during the time of their overdose and subsequent deaths.

<span class="mw-page-title-main">Mephedrone</span> Synthetic stimulant drug

Mephedrone, also known as 4-methylmethcathinone, 4-MMC, and 4-methylephedrone, is a synthetic stimulant drug belonging to the amphetamine and cathinone classes. It is commonly referred to by slang names such as drone, M-CAT, White Magic, meow meow, and bubble. Chemically, it is similar to the cathinone compounds found in the Khat plant, native to eastern Africa.

<span class="mw-page-title-main">Ethcathinone</span> Simulant designer drug

Ethcathinone, also known as ethylpropion or ETH-CAT, is a stimulant drug of the phenethylamine, amphetamine, and cathinone chemical classes. It is an active metabolite of the prodrug diethylcathinone and is fully responsible for its effects. Ethcathinone has been identified as an ingredient in both quasi-legal "party pills", and, along with mephedrone, has also been reported as having been sold as "ecstasy" in the Australian city of Cairns.

<span class="mw-page-title-main">MDAI</span> Chemical compound

MDAI, also known as 5,6-methylenedioxy-2-aminoindane, is an entactogen drug of the 2-aminoindane group which is related to MDMA and produces similar subjective effects.

<span class="mw-page-title-main">Monoamine releasing agent</span> Class of compounds

A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of one or more monoamine neurotransmitters from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitters and hence enhanced signaling by those neurotransmitters. The monoamine neurotransmitters include serotonin, norepinephrine, and dopamine; monoamine releasing agents can induce the release of one or more of these neurotransmitters.

A serotonin–norepinephrine–dopamine releasing agent (SNDRA), also known as a triple releasing agent (TRA), is a type of drug which induces the release of serotonin, norepinephrine/epinephrine, and dopamine in the brain and body. SNDRAs produce euphoriant, entactogen, and psychostimulant effects, and are almost exclusively encountered as recreational drugs.

A serotonin–dopamine releasing agent (SDRA) is a type of drug which induces the release of serotonin and dopamine in the body and/or brain.

<span class="mw-page-title-main">Naphyrone</span> Substituted cathinone stimulant drug

Naphyrone, also known as O-2482 and naphthylpyrovalerone, is a substituted cathinone drug derived from pyrovalerone that acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), producing stimulant effects and has been reported as a novel designer drug. No safety or toxicity data is available on the drug.

<span class="mw-page-title-main">Substituted cathinone</span> Class of chemical compounds

Substituted cathinones, or simply cathinones, which include some stimulants and entactogens, are derivatives of cathinone. They feature a phenethylamine core with an alkyl group attached to the alpha carbon, and a ketone group attached to the beta carbon, along with additional substitutions. Cathinone occurs naturally in the plant khat whose leaves are chewed as a recreational drug.

<span class="mw-page-title-main">3,4-Dimethylmethcathinone</span> Designer stimulant drug

3,4-Dimethylmethcathinone (3,4-DMMC) is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone, apparently produced in response to the banning of mephedrone, following its widespread abuse in many countries in Europe and around the world. 3,4-DMMC has been seized as a designer drug in Australia. In vitro, 3,4-DMMC was shown to be a monoamine transporter substrate that potently inhibits norepinephrine and serotonin reuptake, and to a lesser extent dopamine reuptake.

A monoamine reuptake inhibitor (MRI) is a drug that acts as a reuptake inhibitor of one or more of the three major monoamine neurotransmitters serotonin, norepinephrine, and dopamine by blocking the action of one or more of the respective monoamine transporters (MATs), which include the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). This in turn results in an increase in the synaptic concentrations of one or more of these neurotransmitters and therefore an increase in monoaminergic neurotransmission.

<span class="mw-page-title-main">Bath salts (drug)</span> Recreational drug often superficially resembling true bath salts

Bath salts are a group of recreational designer drugs. The name derives from instances in which the drugs were disguised as bath salts. The white powder, granules, or crystals often resemble Epsom salts, but differ chemically. The drugs' packaging often states "not for human consumption" in an attempt to circumvent drug prohibition laws. Additionally, they may be described as "plant food", "powdered cleaner", or other products.

<span class="mw-page-title-main">4-Chloromethcathinone</span> Simulant drug of the cathinone class

4-Chloromethcathinone is a stimulant drug of the cathinone class that has been sold online as a designer drug.

<span class="mw-page-title-main">Mexedrone</span> Stimulant and entactogen drug

Mexedrone is a stimulant and an entactogen drug of the cathinone class that has been sold online as a designer drug. It is the alpha-methoxy derivative of Mephedrone.

<span class="mw-page-title-main">3-Chloromethcathinone</span> Stimulant designer drug

3-Chloromethcathinone (3-CMC), also known as clophedrone, is a synthetic substance belonging to the cathinone class of psychoactive compounds. It is very similar in structure to other methcathinone derivatives such as 3-MMC and 4-CMC. Unlike cathinone, which occurs naturally in the khat plant Catha edulis, 3-CMC is not found in nature and is solely produced through chemical synthesis.

<span class="mw-page-title-main">3-Methoxymethcathinone</span> Designer drug

3-Methoxymethcathinone (3-MeOMC), also known as meta-methoxymethcathinone (m-MeOMC), is a designer drug of the substituted cathinone family described as a stimulant.

References

  1. 1 2 "News: March 2023 – UNODC: Seven NPS "scheduled" at the 66th Session of the Commission on Narcotic Drugs". United Nations Office on Drugs and Crime (UNODC). United Nations Office on Drugs and Crime. Retrieved 29 May 2024.
  2. 1 2 3 4 5 Shimshoni JA, Britzi M, Sobol E, Willenz U, Nutt D, Edery N (June 2015). "3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics". Journal of Psychopharmacology. 29 (6): 734–43. doi:10.1177/0269881115576687. PMID   25804420. S2CID   26012927.
  3. ↑ "3-Methylmethcathinone (3-MMC) Critical Review Report" (PDF). World Health Organization. Archived from the original (PDF) on 11 November 2021.
  4. ↑ Preedy V (26 April 2016). Neuropathology of Drug Addictions and Substance Misuse Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects (2 ed.). London: King's College. ISBN   978-0-12-800212-4.
  5. 1 2 Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME (May 2018). "Pharmacological profile of mephedrone analogs and related new psychoactive substances" (PDF). Neuropharmacology. 134 (Pt A): 4–12. doi:10.1016/j.neuropharm.2017.07.026. PMID   28755886. S2CID   28786127.
  6. ↑ "EMCDDA 2012 Annual report on the state of the drugs problem in Europe" (PDF). Archived from the original (PDF) on 23 April 2014. Retrieved 17 April 2014.
  7. 1 2 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal (European Database on New Drugs)
  8. ↑ Ferreira B, Dias da Silva D, Carvalho F, de Lourdes Bastos M, Carmo H (February 2019). "The novel psychoactive substance 3-methylmethcathinone (3-MMC or metaphedrone): A review". Forensic Science International. 295: 54–63. doi:10.1016/j.forsciint.2018.11.024. PMID   30572220. S2CID   58638238.
  9. 1 2 Power JD, McGlynn P, Clarke K, McDermott SD, Kavanagh P, O'Brien J (October 2011). "The analysis of substituted cathinones. Part 1: chemical analysis of 2-, 3- and 4-methylmethcathinone". Forensic Science International. 212 (1–3): 6–12. doi:10.1016/j.forsciint.2011.04.020. PMID   21601387.
  10. ↑ Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, Rothman RB (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology. 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC   6475490 . PMID   30341459.
  11. ↑ Frison G, Frasson S, Zancanaro F, Tedeschi G, Zamengo L (August 2016). "Detection of 3-methylmethcathinone and its metabolites 3-methylephedrine and 3-methylnorephedrine in pubic hair samples by liquid chromatography-high resolution/high accuracy Orbitrap mass spectrometry". Forensic Science International. 265: 131–7. doi:10.1016/j.forsciint.2016.01.039. PMID   26901638.
  12. ↑ Schmidt KT, Weinshenker D (April 2014). "Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors". Molecular Pharmacology. 85 (4): 640–50. doi:10.1124/mol.113.090118. PMC   3965894 . PMID   24499709.
  13. ↑ Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). European Monitoring Centre for Drugs and Drug Addiction. 17 March 2022.{{cite book}}: CS1 maint: date and year (link)
  14. ↑ Ameline A, Dumestre-Toulet V, Raul JS, Kintz P (March 2019). "Determination of a threshold fatal 3-MMC concentration in human: mission impossible". Psychopharmacology. 236 (3): 865–867. doi:10.1007/s00213-018-4941-5. PMID   29876621. S2CID   46978121.
  15. 1 2 "3-Methylmethcathinone". Erowid. Retrieved 11 April 2024.
  16. ↑ Sande M (January 2016). "Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users". The International Journal on Drug Policy. 27: 65–73. doi:10.1016/j.drugpo.2015.03.005. PMID   25908121.
  17. ↑ "Lists of: Scheduling Actions Controlled Substances Regulated Chemicals" (PDF). U.S. Department of Justice. February 2023. Retrieved 5 March 2023.
  18. ↑ "eCFR :: 21 CFD 1308.11 (Dec 12, 2023) -- Schedule I." Electronic Code of Federal Regulations. Retrieved 21 December 2023.
  19. ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
  20. ↑ "Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení vlády č. 463/2013 Sb.)" (PDF) (in Czech). Ministerstvo zdravotnictví. Archived from the original (PDF) on 9 March 2016. Retrieved 6 February 2016.
  21. ↑ "Extract from the Report of the 38 th Expert Committee on Drug Dependence, convened from 14 to 18 November 2016, at WHO headquarters in Geneva" (PDF). Commission on Narcotic Drugs. Retrieved 7 December 2016.
  22. ↑ "Designerdrug 3-MMC vanaf vandaag verboden" (in Dutch). Dutch government. 28 October 2021.
  23. 1 2 3 "3-Methylmethcathinone - Clearmind Medicine - AdisInsight". adisinsight.springer.com.
  24. ↑ WO 2019026019,Golan E, Haden M, Van Wettum R,"Use of 3-methylmethcathinone",published 7 February 2019, assigned to Therapeutic Adjuncts Inc.and Recraceutical Corp. B.V.
  25. ↑ WO2021038460A1,JANSSEN, Merel; JANSSEN, Jochem& Golan, Ezekiel,"Treatment of menstrual cycle-induced symptoms",issued 2021-03-04
  26. ↑ "Period Pill • Fixing the Uncomforts of PMS & PMDD". Period Pill. Retrieved 8 May 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.